Johannes B Woehrstein, Co-founder & CEO, mbiomics | Slush 2025
summary
mbiomics claims a reproducible, fermenter-grown synthetic microbiome that doubles immune checkpoint inhibitor response by delivering 150 selected bacterial strains designed in silico from a 14,000-strain library; an AI-first platform maps function to strains, uses deep analytics and co-culturing to manufacture a live-consortium pill, validates in mouse models, and moves MBX‑116 into preclinical now with first human dosing early 2027 and planned efficacy readout mid‑2028; raising a $50M round to run the trial and scale manufacturing.
AI-written summary · about
related talks
16mHow Biology Benefits from Technological Discoveries
25mBiology's ChatGPT Moment
21mShaping the future of health: Boehringer Ingelheim's Data & AI Journey
24mTechnology’s Next Frontiers
44mNext-Gen Therapies
26mShiva Amiri, CEO, BioSymetrics at MLconf Seattle 2017
08mAnne Wojcicki interviewed at Web 2.0 Summit 2011
39mThe Translation Gap
